SCHEMBL1482687

SCHEMBL1482687

Fc1cc2nc(-c3cccnc3Cl)n(CC3CCCCC3)c2cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.49
HPGD P15428 1/20 0.49
NR1H4 Q96RI1 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 3/20 0.43
ALOX5 P09917 2/20 0.43
GAA P10253 1/20 0.43
RECQL P46063 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP11B2 P19099 2/20 0.40
VDR P11473 1/20 0.39
CYP11B1 P15538 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482027 0.87 NR1H4 (0.43) KDM4ELMNAALDH1A1NR1H4NPSR1
SCHEMBL1483031 0.85 FFAR4 (0.41) NR1H4ALOX5MEN1KMT2ACYP11B2
SCHEMBL1482405 0.84 ALOX5AP (0.42) NR1H4ALOX5CYP11B2VDRCYP11B1
SCHEMBL1482617 0.82 HTR2A (0.42) KDM4ELMNAALDH1A1HPGDNR1H4
SCHEMBL1577199 0.82 NPSR1 (0.40) KDM4ELMNAALDH1A1HPGDCYP1A2
SCHEMBL1482720 0.81 NR1H4 (0.43) KDM4EALDH1A1NR1H4NPSR1ALOX5
SCHEMBL1482656 0.81 NR1H4 (0.45) KDM4ELMNAALDH1A1HPGDNR1H4
SCHEMBL1482246 0.80 NR1H4 (0.55) NR1H4CYP2C9ALOX5MEN1KMT2A
SCHEMBL1484226 0.79 KDM4E (0.72) KDM4ELMNAALDH1A1HPGDCYP1A2
SCHEMBL1482629 0.79 NR1H4 (0.53) NR1H4CYP2C9ALOX5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 KDM4E 1791/4885LMNA 2064/4885ALDH1A1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.